Screener Summaries Updates Institutions Sign In More Updates › Other Events › AVLN Other Events · Jun 17, 2026
Avalyn Pharma Inc. announced on June 17, 2026, that it has completed target enrollment for its Phase 2b MIST trial of… AVLN Avalyn Pharma Inc.
Avalyn Pharma Inc. announced on June 17, 2026, that it has completed target enrollment for its Phase 2b MIST trial of AP01 (inhaled pirfenidone) for patients with progressive pulmonary fibrosis. Avalyn Pharma Inc. is a pharmaceutical company focused on developing therapeutic solutions for pulmonary diseases.
More from Avalyn Pharma Inc. Avalyn Pharma Inc. appointed Robert Meyer, M.D., as a Class II director effective September 15, 2026, with his term… Sep 16, 2026 Avalyn Pharma Inc. reported financial results for the quarter ended June 30, 2026, reporting a net loss of $28.9… Aug 12, 2026 On June 29, 2026, Avalyn Pharma Inc. entered into a First Amendment to its Sublease Agreement with CRISPR… Jul 1, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
